TICKER: FSDC
Company: FS Development Corp.
Company: FS Development Corp.
Ticker: FSDC
Stage: 4. Deal Approved
Size:
Latest Price:
Previous close:
All time high price:
Volume:
Average volume:
FOLLOW SPAC
DISCOVER NEW FRIENDS
GET AHEAD OF THE GAME
FS Development Corp. is listed on the stock exchange with the ticker FSDC,
FSDC SPAC all time high was and the lowest price in the last 52 week was: ,
the current FSDC stock price is . FSDC has an overall market cap of: .
The latest volume was: .
FSDC is currently in stage: 4. Deal Approved.
You can read all about FSDC and it’s information about the SPAC, news, SEC filings and more on our special data platform.
Want to know more about FSDC and FS Development Corp.? Join us today.
FSDC SPAC all time high was and the lowest price in the last 52 week was: ,
the current FSDC stock price is . FSDC has an overall market cap of: .
The latest volume was: .
FSDC is currently in stage: 4. Deal Approved.
You can read all about FSDC and it’s information about the SPAC, news, SEC filings and more on our special data platform.
Want to know more about FSDC and FS Development Corp.? Join us today.
- Precision medicine in AMD: a SPAC merger takes Gemini public – pharmaceutical-technology.com
- Foresite Capital Jumps Back Into SPAC Frenzy With Second Shell Company – BioSpace
- FS Development II prices upsized $175M IPO – Seeking Alpha
- Foresite Capital's second SPAC FS Development II raises deal size by 50% ahead of $150 million IPO – Nasdaq
- Biotech Gemini Therapeutics sinks 7.6% on first trading day – Seeking Alpha
- Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration – Business Wire
- Gemini Therapeutics Hits the Nasdaq Following SPAC Merger – BioSpace
- Gemini Therapeutics' Merger Agreement With FS Development Corp – Global Legal Chronicle
- 5 SPAC Stocks That Announced New Mergers This Week – Nasdaq
- Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration – Business Wire
- Why This Top Venture Capitalist Is Raising Money With a Biotech SPAC – Motley Fool
- U.S. IPO Weekly Recap: Coronavirus Vaccine Developer CureVac Pops 249% In A 4-IPO Week – Seeking Alpha
- Foresite Capital's SPAC FS Development prices upsized $105 million IPO at $10 – Nasdaq
- SoftBank-Backed Fortress SPAC Leads 2 IPOs Totaling $405M – Law360
- Rocket Companies scheduled to enter the Renaissance IPO ETF (ticker: IPO) – Nasdaq
[finviz ticker=FSDC]